Phone app monitoring for pregnant women with high blood pressure or diabetes
Tests a phone app for home monitoring in pregnant women with hypertension or diabetes.
Plain-language title generated from the registry record
Registry title: Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and/or Diabetes (MOM-HD)
Key facts
- Where
- Biratnagar, Dhulikhel, and Kathmandu, NepalSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women aged 18 or older with high blood pressure or gestational diabetes, who have a smartphone and are up to 34 weeks pregnant.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Chronic high blood pressure, gestational high blood pressure or preeclampsia without severe features, or gestational diabetes. Up to 34 weeks of pregnancy at enrolment.
- Biomarker or test result
- High blood pressure means 140 mm Hg or more (top number) and/or 90 mm Hg or more (bottom number), or being on blood pressure medicine before 20 weeks of pregnancy.
Main reasons for not taking part
- Pregnancy with more than one baby
- Severe illness needing hospital care, such as preeclampsia with severe features, eclampsia or HELLP syndrome
- Difficulty communicating, for example hearing, speech or thinking problems
- Cannot understand the Nepali language
- Declines to give informed consent
This trial only enrols pregnant participants. The registry sentence this rests on: Pregnant women receiving antenatal care at RCT site
Read by machine on 12 November 2026.
Where in Nepal
- Nobel Medical College Teaching HospitalBiratnagar, NepalContact: Isha PuuriTaking people
- Dhulikhel HospitalDhulikhel, NepalContact: Archana ShresthaTaking people
- Paropakar Maternity and Women's HospitalKathmandu, NepalContact: Yunika AcharyaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Rutgers, The State University of New Jersey
- Trial code
- NCT07243886
- Record updated
- 31 July 2026
- Original description
Hypertensive disorders during pregnancy (HDP) and gestational diabetes (GDM) are among the leading complications in pregnancy, significantly contributing to global maternal and fetal morbidity and mortality. (1,2,3) Effective management of HDP and GDM hinges on regular monitoring of blood pressure (BP) and blood glucose (BG) to ensure adequate control and timely interventions for maternal and fetal well-being. Telemonitoring offers a promising and cost-effective alternative by enabling pregnant individuals to monitor BP and BG at home and share real-time results with healthcare providers, facilitating informed clinical decision-making and timely interventions.Read full original descriptionShow less
Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and/or Diabetes (MOM-HD): a Type II Hybrid Implementation-Effectiveness Trial
Hypertensive disorders during pregnancy (HDP) and gestational diabetes (GDM) are among the leading complications in pregnancy, significantly contributing to global maternal and fetal morbidity and mortality. (1,2,3) Effective management of HDP and GDM hinges on regular monitoring of blood pressure (BP) and blood glucose (BG) to ensure adequate control and timely interventions for maternal and fetal well-being. Telemonitoring offers a promising and cost-effective alternative by enabling pregnant individuals to monitor BP and BG at home and share real-time results with healthcare providers, facilitating informed clinical decision-making and timely interventions.
Here the investigators propose to conduct a Hybrid Type II Effectiveness-Implementation Randomized Controlled Trial (RCT) to assess the effectiveness and evaluate the implementation of the MOM-HD (Mobile-based Obstetric Monitoring for Hypertension and/or Diabetes) program, a mobile app-based perinatal telemonitoring program, in real-world clinical settings in Nepal. To address the study aims, the investigators will recruit 864 women who are newly diagnosed with HDP and GDM from three metropolitan hospitals and randomly assign them to either (i) MOM-HD + standard care or (ii) standard care alone, from enrolment in pregnancy to 6 weeks postpartum. Primary and secondary clinical outcomes will be assessed at delivery, and at 6 weeks postpartum. The investigators hypothesize that compared to standard care, the use of MOM-HD in addition to standard care will result in lower systolic BP levels, lower incidence rate for the composite adverse perinatal outcome of either perinatal loss, neonatal intensive care unit admission, primary cesarean delivery or labor induction, and lower proportion of days with elevated systolic BP or BG readings between recruitment and 6 weeks postpartum. A convergent mixed-methods approach will be used to assess implementation and maintenance outcomes using the RE-AIM framework (4), and economic sustainability will be assessed by collecting primary cost data.
Inclusion: Pregnant women receiving antenatal care at RCT site; Diagnosed with one of the following:; Chronic hypertension (sustained systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg, or on antihypertensive treatment before 20 weeks of gestation); Gestational hypertension or preeclampsia without severe features (sustained systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg after 20 weeks of gestation); Gestational diabetes; Age 18 years or older; Access to a smartphone; Gestational age ≤ 34 weeks at enrollment; Able to read and write.
Exclusion: Severe maternal illness or any condition that precludes active study participation (e.g., preeclampsia with severe features, eclampsia, HELLP syndrome, or other conditions requiring inpatient management); Multifetal pregnancies; Apparent communication difficulties (e.g., hearing, speech, or cognitive impairments), as judged by research assistants; Unable to understand the Nepali language; Declines to provide informed consent.